Hing C. Wong Amends HCW Biologics Stake Filing

TL;DR

Hing C. Wong updated their 13D filing for HCW Biologics Inc. - check for changes in ownership.

AI Summary

Hing C. Wong, through HCW Biologics Inc., filed an amendment (No. 1) to their Schedule 13D on November 22, 2024, regarding their holdings in HCW Biologics Inc. The filing indicates a change in the reporting person's status or holdings as of November 20, 2024. The company is in the pharmaceutical preparations industry.

Why It Matters

This amendment signals a potential shift in significant ownership or control of HCW Biologics Inc., which could impact the company's stock price and strategic direction.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D often indicate significant changes in beneficial ownership, which can lead to increased stock volatility.

Key Numbers

• 1 — Amendment Number (Indicates this is an update to a previous filing.)
• 20241122 — Filing Date (Date the amendment was officially submitted to the SEC.)
• 20241120 — Date of Change (Date of the event requiring the filing amendment.)

Key Players & Entities

• Hing C. Wong (person) — Reporting Person
• HCW Biologics Inc. (company) — Subject Company
• 2929 N. Commerce Parkway, Miramar, FL 33025 (address) — Company and Filing Person's Address

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $15,925,800 — $ Previously reported 15,255,618 $15,925,800 Transaction 8/30/2021 26,330 $101
• $101,639.75 — ,800 Transaction 8/30/2021 26,330 $101,639.75 Transaction 9/7/2022 20,000 $52,5
• $52,560.00 — 39.75 Transaction 9/7/2022 20,000 $52,560.00 Transaction 6/9/2022 3000 $6,800.
• $6,800.00 — ,560.00 Transaction 6/9/2022 3000 $6,800.00 Transaction 6/13/2022 1520 $3,325
• $3,325.76 — 800.00 Transaction 6/13/2022 1520 $3,325.76 Transaction 5/30/2023 6,600 $10,2
• $10,272.58 — 25.76 Transaction 5/30/2023 6,600 $10,272.58 Transaction 9/14/2023 1,800 $3,74
• $3,740.76 — 72.58 Transaction 9/14/2023 1,800 $3,740.76 Transaction 2/20/2024 739,288 $1,
• $1,400,000.00 — .76 Transaction 2/20/2024 739,288 $1,400,000.00 Total 16,054,156 $17,504,139.00
• $17,504,139.00 — $1,400,000.00 Total 16,054,156 $17,504,139.00 Item 5. Interest in Securities of the

Filing Documents

• 13da_20241122_hing_c_won.htm (SC 13D/A) — 70KB
• 0000950170-24-130268.txt ( ) — 71KB

Source and Amount of Funds

Item 3. Source and Amount of Funds The Reporting Person used personal funds to acquire additional shares, in the amounts shown below, the securities of the Company. Securities Number of Shares # Amount Paid $ Previously reported 15,255,618 $15,925,800 Transaction 8/30/2021 26,330 $101,639.75 Transaction 9/7/2022 20,000 $52,560.00 Transaction 6/9/2022 3000 $6,800.00 Transaction 6/13/2022 1520 $3,325.76 Transaction 5/30/2023 6,600 $10,272.58 Transaction 9/14/2023 1,800 $3,740.76 Transaction 2/20/2024 739,288 $1,400,000.00 Total 16,054,156 $17,504,139.00

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer On November 20, 2024, HCW Biologics Inc. closed on a registered direct offering where it issued 4,160,000 shares of the Company’s common stock, par value $0.0001 per share, and pre-funded warrants to purchase up to 2,557,000 shares of common stock to a single institutional investor. On November 20, 2024, the institutional investor exercised all its pre-funded warrants and the Company issued 2,557,000 of registered Common Stock. This transaction decreased Reporting Person’s beneficial ownership as follows. (a)-(b) The Reporting Person has beneficial ownership of 16,054,156 shares of Common Stock. The percentage of beneficial ownership is approximately 36.04% of outstanding shares of Common Stock. The percentage of Common Stock is based on 44,540,394 shares of Common Stock as of November 22, 2024. The Reporting Person has the sole power to dispose or direct the disposition of all shares of Common Stock that the Reporting Person beneficially owned as of November 22, 2024, except for 4,127,619 shares of Common Stock which he shares the power to dispose or direct the disposition of with his spouse, Ms. Bee Yau Huang. (c) The Reporting Person has not effected any transactions in Common Stock in the last 60 days.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer The Reporting Person has entered into an agreement with the Company and the single institutional investor to which he has agreed not to sell, transfer, pledge or otherwise dispose of any of the shares of Common Stock for a period of 90 days after the date of the closing date of the registered direct transaction.

Material to be Filed as Exhibits

Item 7. Material to be Filed as Exhibits. No exhibits to be filed. 3

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I hereby certify that the information set forth in this statement is true, complete and correct. HCW BIOLOGICS INC. Date: November 22, 2024 By: /s/ Hing C. Wong Hing C. Wong Founder and Chief Executive Officer

View Full Filing

View this SC 13D/A filing on SEC EDGAR